Download PDF
CC BY-NC-ND 4.0 · Journal of Gastrointestinal Infections 2023; 13(01): 001-016
DOI: 10.1055/s-0043-1768145
Review Article

Review: Microbial Therapeutics for Liver Disease

Cyriac Abby Philips 
1   Clinical and Translational Hepatology and Monarch Liver Laboratory, The Liver Institute, Center for Excellence in Gastrointestinal Sciences, Rajagiri Hospital, Aluva, Kerala, India
,
Philip Augustine
2   Gastroenterology and Advanced GI Endoscopy, Center for Excellence in Gastrointestinal Sciences, Rajagiri Hospital, Aluva, Kerala, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

The human gut contains many microorganisms, including bacteria, fungi, viruses, and archaea. Patients with liver disorders have altered intestinal flora and disrupted gut barriers. The role of the gut microbiota in the pathophysiology of many liver disorders is apparent from preclinical models and clinical studies. High-quality studies showed that people with acute or chronic liver disorders of various etiologies, such as non–alcohol- and alcohol-related liver disease, chronic hepatitis virus infection, chronic cholestatic liver disease, and liver cirrhosis and related complications, have less diverse gut flora and associated perturbed microbial functional metabolism. In this review, we discuss unique therapeutic strategies for various liver diseases that involve manipulating the gut microbiota using various methods. We provide a summary of the most recent information on untargeted methods for treating liver illnesses, such as probiotics, prebiotics, and postbiotics, fecal microbiota transplantation, and precision microbiome-centered treatments (e.g., engineered microbes). Recent research suggests that altering the gut microbiota in various ways might slow the onset of liver disease and lessen the associated clinical complications. Growing evidence suggests that antimicrobial therapy with rifaximin can beneficially alter the gut microbiome to reduce hepatic encephalopathy, portal hypertension, and systemic inflammation in decompensated cirrhosis. At the same time, a healthy donor stool transplant improves transplant-free survival in severe alcohol-associated hepatitis, prevents hepatic encephalopathy, and reduces incident and intercurrent infections and multidrug resistance in decompensated cirrhosis.

Keywords

gut microbiome - NAFLD - sepsis - hepatic encephalopathy - hepatocellular carcinoma - HBV - HCV - DILI

Author Contributions

C.A.P.: conceptualization, writing - original draft, writing - review and editing. P.A.: supervision, writing - review and editing.




Publication History

Received: 19 January 2023

Accepted: 02 March 2023

Article published online:
22 September 2023

© 2023. Gastroinstestinal Infection Society of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol 2015; 31 (01) 69-75
    CrossrefPubMedGoogle Scholar
  • 2 Iqbal S, Quigley EM. Progress in our understanding of the gut microbiome: implications for the clinician. Curr Gastroenterol Rep 2016; 18 (09) 49
    CrossrefPubMedGoogle Scholar
  • 3 Adolph TE, Grander C, Moschen AR, Tilg H. Liver-microbiome axis in health and disease. Trends Immunol 2018; 39 (09) 712-723
    CrossrefPubMedGoogle Scholar
  • 4 Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014; 146 (06) 1513-1524
    CrossrefPubMedGoogle Scholar
  • 5 Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J 2017; 474 (11) 1823-1836
    CrossrefPubMedGoogle Scholar
  • 6 Cianci R, Pagliari D, Piccirillo CA, Fritz JH, Gambassi G. The microbiota and immune system crosstalk in health and disease. Mediators Inflamm 2018; 2018: 2912539
    CrossrefPubMedGoogle Scholar
  • 7 Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases. Cell Mol Immunol 2021; 18 (01) 4-17
    CrossrefPubMedGoogle Scholar
  • 8 Tripathi A, Debelius J, Brenner DA. et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018; 15 (07) 397-411
    CrossrefPubMedGoogle Scholar
  • 9 Shen TD, Pyrsopoulos N, Rustgi VK. Microbiota and the liver. Liver Transpl 2018; 24 (04) 539-550
    CrossrefPubMedGoogle Scholar
  • 10 Haque TR, Barritt IV AS. Intestinal microbiota in liver disease. Best Pract Res Clin Gastroenterol 2016; 30 (01) 133-142
    CrossrefPubMedGoogle Scholar
  • 11 Milosevic I, Vujovic A, Barac A. et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci 2019; 20 (02) 395
    CrossrefPubMedGoogle Scholar
  • 12 Anand G, Zarrinpar A, Loomba R. Targeting dysbiosis for the treatment of liver disease. Semin Liver Dis 2016; 36 (01) 37-47
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Wirusanti NI, Baldridge MT, Harris VC. Microbiota regulation of viral infections through interferon signaling. Trends Microbiol 2022; 30 (08) 778-792
    CrossrefPubMedGoogle Scholar
  • 14 Wu J, Bortolanza M, Zhai G. et al. Gut microbiota dysbiosis associated with plasma levels of Interferon-γ and viral load in patients with acute hepatitis E infection. J Med Virol 2022; 94 (02) 692-702
    CrossrefPubMedGoogle Scholar
  • 15 Shu W, Shanjian C, Jinpiao L, Qishui O. Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis. Ann Hepatol 2022; 27 (02) 100676
    CrossrefPubMedGoogle Scholar
  • 16 Chen B, Huang H, Pan CQ. The role of gut microbiota in hepatitis B disease progression and treatment. J Viral Hepat 2022; 29 (02) 94-106
    CrossrefPubMedGoogle Scholar
  • 17 Tang Y, Zhou H, Xiang Y, Cui F. The diagnostic potential of gut microbiome for early hepatitis B virus-related hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2021; 33 (1S, Suppl 1): e167-e175
    CrossrefPubMedGoogle Scholar
  • 18 Li YN, Kang NL, Jiang JJ. et al. Gut microbiota of hepatitis B virus-infected patients in the immune-tolerant and immune-active phases and their implications in metabolite changes. World J Gastroenterol 2022; 28 (35) 5188-5202
    CrossrefPubMedGoogle Scholar
  • 19 Li YG, Yu ZJ, Li A, Ren ZG. Gut microbiota alteration and modulation in hepatitis B virus-related fibrosis and complications: molecular mechanisms and therapeutic inventions. World J Gastroenterol 2022; 28 (28) 3555-3572
    CrossrefPubMedGoogle Scholar
  • 20 Marascio N, De Caro C, Quirino A. et al. The role of the microbiota gut-liver axis during HCV chronic infection: a schematic overview. J Clin Med 2022; 11 (19) 5936
    CrossrefPubMedGoogle Scholar
  • 21 Huang PY, Chen CH, Tsai MJ. et al. Effects of direct anti-viral agents on the gut microbiota in patients with chronic hepatitis C. J Formos Med Assoc 2023; 122 (02) 157-163
    CrossrefPubMedGoogle Scholar
  • 22 Kobayashi T, Iwaki M, Nakajima A, Nogami A, Yoneda M. Current research on the pathogenesis of NAFLD/NASH and the gut-liver axis: gut microbiota, dysbiosis, and leaky-gut syndrome. Int J Mol Sci 2022; 23 (19) 11689
    CrossrefPubMedGoogle Scholar
  • 23 Jadhav K, Cohen TS. Can you trust your gut? Implicating a disrupted intestinal microbiome in the progression of NAFLD/NASH. Front Endocrinol (Lausanne) 2020; 11: 592157
    CrossrefPubMedGoogle Scholar
  • 24 Vallianou N, Christodoulatos GS, Karampela I. et al. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives. Biomolecules 2021; 12 (01) 56
    CrossrefPubMedGoogle Scholar
  • 25 Zhang Y, Yan S, Sheng S. et al. Comparison of gut microbiota in male MAFLD patients with varying liver stiffness. Front Cell Infect Microbiol 2022; 12: 873048
    CrossrefPubMedGoogle Scholar
  • 26 Meijnikman AS, Davids M, Herrema H. et al. Microbiome-derived ethanol in nonalcoholic fatty liver disease. Nat Med 2022; 28 (10) 2100-2106
    CrossrefPubMedGoogle Scholar
  • 27 Araujo R, Borges-Canha M, Pimentel-Nunes P. Microbiota modulation in patients with metabolic syndrome. Nutrients 2022; 14 (21) 4490
    CrossrefPubMedGoogle Scholar
  • 28 Zafari N, Velayati M, Fahim M. et al. Role of gut bacterial and non-bacterial microbiota in alcohol-associated liver disease: molecular mechanisms, biomarkers, and therapeutic prospective. Life Sci 2022; 305: 120760
    CrossrefPubMedGoogle Scholar
  • 29 Chen L, Zhu Y, Hou X, Yang L, Chu H. The role of gut bacteria and fungi in alcohol-associated liver disease. Front Med (Lausanne) 2022; 9: 840752
    CrossrefPubMedGoogle Scholar
  • 30 Philips CA, Augustine P, Ganesan K. et al. The role of gut microbiota in clinical complications, disease severity, and treatment response in severe alcoholic hepatitis. Indian J Gastroenterol 2022; 41 (01) 37-51
    CrossrefPubMedGoogle Scholar
  • 31 Philips CA, Schnabl B, Bajaj JS. Gut microbiome and alcohol-associated liver disease. J Clin Exp Hepatol 2022; 12 (05) 1349-1359
    CrossrefPubMedGoogle Scholar
  • 32 Bajaj JS. Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol Hepatol 2019; 16 (04) 235-246
    CrossrefPubMedGoogle Scholar
  • 33 Manzoor R, Ahmed W, Afify N. et al. Trust your gut: the association of gut microbiota and liver disease. Microorganisms 2022; 10 (05) 1045
    CrossrefPubMedGoogle Scholar
  • 34 Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A 2009; 106 (34) 14728-14733
    CrossrefPubMedGoogle Scholar
  • 35 Gong S, Lan T, Zeng L. et al. Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice. J Hepatol 2018; 69 (01) 51-59
    CrossrefPubMedGoogle Scholar
  • 36 Sun X, Cui Q, Ni J. et al. Gut microbiota mediates the therapeutic effect of monoclonal anti-TLR4 antibody on acetaminophen-induced acute liver injury in mice [retraction of: Sun X, Cui Q, Ni J, et al. In: Microbiol Spectr 2022;10(3):e0064722]. Microbiol Spectr 2023; 11 (01) e0311622
    PubMedGoogle Scholar
  • 37 Yip LY, Aw CC, Lee SH. et al. The liver-gut microbiota axis modulates hepatotoxicity of tacrine in the rat. Hepatology 2018; 67 (01) 282-295
    CrossrefPubMedGoogle Scholar
  • 38 Feng W, Ao H, Peng C. Gut microbiota, short-chain fatty acids, and herbal medicines. Front Pharmacol 2018; 9: 1354
    CrossrefPubMedGoogle Scholar
  • 39 Wei Y, Li Y, Yan L. et al. Alterations of gut microbiome in autoimmune hepatitis. Gut 2020; 69 (03) 569-577
    CrossrefPubMedGoogle Scholar
  • 40 Jiang H, Yan R, Wang K. et al. Lactobacillus reuteri DSM 17938 alleviates d-galactosamine-induced liver failure in rats. Biomed Pharmacother 2021; 133: 111000
    CrossrefPubMedGoogle Scholar
  • 41 Philips CA, Augustine P, Yerol PK. et al. Modulating the intestinal microbiota: therapeutic opportunities in liver disease. J Clin Transl Hepatol 2020; 8 (01) 87-99
    PubMedGoogle Scholar
  • 42 Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol 2021; 75 (Suppl 1, Suppl 1): S67-S81
    CrossrefPubMedGoogle Scholar
  • 43 Lee NY, Suk KT. The role of the gut microbiome in liver cirrhosis treatment. Int J Mol Sci 2020; 22 (01) 199
    CrossrefPubMedGoogle Scholar
  • 44 Philips CA, Augustine P. Gut barrier and microbiota in cirrhosis. J Clin Exp Hepatol 2022; 12 (02) 625-638
    CrossrefPubMedGoogle Scholar
  • 45 Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. Am J Physiol Gastrointest Liver Physiol 2020; 318 (01) G84-G98
    CrossrefPubMedGoogle Scholar
  • 46 Philips CA, Ahamed R, Abduljaleel JKP, Rajesh S, Augustine P. Identification and analysis of gut microbiota and functional metabolism in decompensated cirrhosis with infection. J Clin Transl Hepatol 2023; 11 (01) 15-25
    PubMedGoogle Scholar
  • 47 Chen Y, Ji F, Guo J, Shi D, Fang D, Li L. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Sci Rep 2016; 6: 34055
    CrossrefPubMedGoogle Scholar
  • 48 Li K, Liu J, Qin X. Research progress of gut microbiota in hepatocellular carcinoma. J Clin Lab Anal 2022; 36 (07) e24512
    CrossrefPubMedGoogle Scholar
  • 49 Kang Y, Cai Y, Yang Y. The gut microbiome and hepatocellular carcinoma: implications for early diagnostic biomarkers and novel therapies. Liver Cancer 2021; 11 (02) 113-125
    CrossrefPubMedGoogle Scholar
  • 50 Luo W, Guo S, Zhou Y. et al. Hepatocellular carcinoma: how the gut microbiota contributes to pathogenesis, diagnosis, and therapy. Front Microbiol 2022; 13: 873160
    CrossrefPubMedGoogle Scholar
  • 51 Schneider KM, Mohs A, Gui W. et al. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. Nat Commun 2022; 13 (01) 3964
    CrossrefPubMedGoogle Scholar
  • 52 Floreani A, De Martin S, Ikeura T, Okazaki K, Gershwin ME. Gut microbial profiling as a therapeutic and diagnostic target for managing primary biliary cholangitis. Expert Opin Orphan Drugs 2020; 8 (12) 507-514
    CrossrefGoogle Scholar
  • 53 Tang R, Wei Y, Li Y. et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 2018; 67 (03) 534-541
    CrossrefPubMedGoogle Scholar
  • 54 Little R, Wine E, Kamath BM, Griffiths AM, Ricciuto A. Gut microbiome in primary sclerosing cholangitis: a review. World J Gastroenterol 2020; 26 (21) 2768-2780
    CrossrefPubMedGoogle Scholar
  • 55 Yan S, Yin XM. Gut microbiome in liver pathophysiology and cholestatic liver disease. Liver Res 2021; 5 (03) 151-163
    CrossrefPubMedGoogle Scholar
  • 56 Liu C, Wang YL, Yang YY. et al. Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. FASEB J 2021; 35 (10) e21871
    PubMedGoogle Scholar
  • 57 Moreau R, Elkrief L, Bureau C. et al; NORFLOCIR Trial Investigators. Effects of long-term norfloxacin therapy in patients with advanced cirrhosis. Gastroenterology 2018; 155 (06) 1816-1827.e9
    CrossrefPubMedGoogle Scholar
  • 58 The Antibiocor Trial. Accessed January 11, 2023 at: https://www.thelancet.com/pdfs/journals/langas/PIIS2468-1253(21)00269-7.pdf
  • 59 Støy S, Laursen TL, Eriksen LL, Grønbæk H, Vilstrup H, Sandahl TD. No effect in alcoholic hepatitis of gut-selective, broad-spectrum antibiotics on bacterial translocation or hepatic and systemic inflammation. Clin Transl Gastroenterol 2021; 12 (02) e00306
    CrossrefPubMedGoogle Scholar
  • 60 Lanthier N, Delzenne N. Targeting the gut microbiome to treat metabolic dysfunction-associated fatty liver disease: ready for prime time?. Cells 2022; 11 (17) 2718
    CrossrefPubMedGoogle Scholar
  • 61 Li S, Liu J, Wang Z. et al. The promising role of probiotics/prebiotics/synbiotics in energy metabolism biomarkers in patients with NAFLD: a systematic review and meta-analysis. Front Public Health 2022; 10: 862266
    CrossrefPubMedGoogle Scholar
  • 62 Xing W, Gao W, Lv X. et al. The effects of supplementation of probiotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Front Nutr 2022; 9: 1024678
    CrossrefPubMedGoogle Scholar
  • 63 Wang Q, Shi J, Zhao M. et al. Microbial treatment of alcoholic liver disease: a systematic review and meta-analysis. Front Nutr 2022; 9: 1054265
    CrossrefPubMedGoogle Scholar
  • 64 Dewanjee S, Dua TK, Paul P. et al. Probiotics: evolving as a potential therapeutic option against acetaminophen-induced hepatotoxicity. Biomedicines 2022; 10 (07) 1498
    CrossrefPubMedGoogle Scholar
  • 65 Maslennikov R, Ivashkin V, Efremova I, Poluektova E, Shirokova E. Probiotics in hepatology: an update. World J Hepatol 2021; 13 (09) 1154-1166
    CrossrefPubMedGoogle Scholar
  • 66 Philips CA, Ahamed R, Abduljaleel JK, Rajesh S, Tharakan A, Augustine P. 680: Clinical outcomes and gut microbiome changes associated with high dose probiotic infusion therapy in patients with alcohol-associated hepatitis–comparisons with corticosteroids and fecal transplantation. Gastroenterology 2022; 162 (07) S-1136
    CrossrefGoogle Scholar
  • 67 Philips CA, Ahamed R, Rajesh S, Augustine P. ‘You know my name, but not my story’ - Deciding on an accurate nomenclature for faecal microbiota transplantation. J Hepatol 2020; 72 (06) 1212-1213
    CrossrefPubMedGoogle Scholar
  • 68 Ren YD, Ye ZS, Yang LZ. et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy. Hepatology 2017; 65 (05) 1765-1768
    CrossrefPubMedGoogle Scholar
  • 69 Chauhan A, Kumar R, Sharma S. et al. Fecal microbiota transplantation in hepatitis B e antigen-positive chronic hepatitis B patients: a pilot study. Dig Dis Sci 2021; 66 (03) 873-880
    CrossrefPubMedGoogle Scholar
  • 70 Bajaj JS, Kassam Z, Fagan A. et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 2017; 66 (06) 1727-1738
    CrossrefPubMedGoogle Scholar
  • 71 Bajaj JS, Salzman N, Acharya C. et al. Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis. JCI Insight 2019; 4 (24) e133410
    CrossrefPubMedGoogle Scholar
  • 72 Bajaj JS, Salzman NH, Acharya C. et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial. Hepatology 2019; 70 (05) 1690-1703
    CrossrefPubMedGoogle Scholar
  • 73 Mehta R, Kabrawala M, Nandwani S. et al. Preliminary experience with single fecal microbiota transplant for treatment of recurrent overt hepatic encephalopathy-a case series. Indian J Gastroenterol 2018; 37 (06) 559-562
    CrossrefPubMedGoogle Scholar
  • 74 Bajaj JS, Shamsaddini A, Fagan A. et al. Fecal microbiota transplant in cirrhosis reduces gut microbial antibiotic resistance genes: analysis of two trials. Hepatol Commun 2020; 5 (02) 258-271
    CrossrefPubMedGoogle Scholar
  • 75 Bloom PP, Donlan J, Torres Soto M, Daidone M, Hohmann E, Chung RT. Fecal microbiota transplant improves cognition in hepatic encephalopathy and its effect varies by donor and recipient. Hepatol Commun 2022; 6 (08) 2079-2089
    CrossrefPubMedGoogle Scholar
  • 76 Craven L, Rahman A, Nair Parvathy S. et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol 2020; 115 (07) 1055-1065
    CrossrefPubMedGoogle Scholar
  • 77 Xue L, Deng Z, Luo W, He X, Chen Y. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial. Front Cell Infect Microbiol 2022; 12: 759306
    CrossrefPubMedGoogle Scholar
  • 78 Witjes JJ, Smits LP, Pekmez CT. et al. Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis. Hepatol Commun 2020; 4 (11) 1578-1590
    CrossrefPubMedGoogle Scholar
  • 79 Philips CA, Pande A, Shasthry SM. et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study. Clin Gastroenterol Hepatol 2017; 15 (04) 600-602
    CrossrefPubMedGoogle Scholar
  • 80 Philips CA, Phadke N, Ganesan K, Ranade S, Augustine P. Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis. Indian J Gastroenterol 2018; 37 (03) 215-225
    CrossrefPubMedGoogle Scholar
  • 81 Philips CA, Ahamed R, Rajesh S, Abduljaleel JKP, Augustine P. Long-term outcomes of stool transplant in alcohol-associated hepatitis-analysis of clinical outcomes, relapse, gut microbiota and comparisons with standard care. J Clin Exp Hepatol 2022; 12 (04) 1124-1132
    CrossrefPubMedGoogle Scholar
  • 82 Philips CA, Augustine P, Padsalgi G, Ahamed R, Jose A, Rajesh S. Only in the darkness can you see the stars: severe alcoholic hepatitis and higher grades of acute-on-chronic liver failure. J Hepatol 2019; 70 (03) 550-551
    CrossrefPubMedGoogle Scholar
  • 83 Sharma A, Roy A, Premkumar M. et al. Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial. Hepatol Int 2022; 16 (02) 433-446
    CrossrefPubMedGoogle Scholar
  • 84 Pande A, Sharma S, Khillan V. et al. Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial. Hepatol Int 2023; 17 (01) 249-261
    CrossrefPubMedGoogle Scholar
  • 85 Philips CA, Ahamed R, Rajesh S. et al. Clinical outcomes and gut microbiota analysis of severe alcohol-associated hepatitis patients undergoing healthy donor fecal transplant or pentoxifylline therapy: single-center experience from Kerala. Gastroenterol Rep (Oxf) 2022; 10: goac074
    CrossrefPubMedGoogle Scholar
  • 86 Duan Y, Llorente C, Lang S. et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 2019; 575 (7783): 505-511
    CrossrefPubMedGoogle Scholar
  • 87 Philips CA, Augustine P, Phadke N. Healthy donor fecal microbiota transplantation for recurrent bacterial cholangitis in primary sclerosing cholangitis - a single case report. J Clin Transl Hepatol 2018; 6 (04) 438-441
    PubMedGoogle Scholar
  • 88 Allegretti JR, Kassam Z, Carrellas M. et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Am J Gastroenterol 2019; 114 (07) 1071-1079
    CrossrefPubMedGoogle Scholar